Genomic landscape of hyperleukocytic acute myeloid leukemia - Université Toulouse III - Paul Sabatier - Toulouse INP Accéder directement au contenu
Article Dans Une Revue Blood Cancer Journal Année : 2022

Genomic landscape of hyperleukocytic acute myeloid leukemia

Résumé

Approximately 20% of patients with acute myeloid leukemia (AML) present at diagnosis with hyperleukocytosis, which is commonly defined as a white blood cell count > 50 ×109 /L or >100 ×109 /L. Hyperleukocytic AML is an oncological emergency because the risk of early death is significant due to leukemic organ infiltration, leukostasis syndrome, disseminated intravascular coagulopathy and tumour lysis syndrome. Early management of these symptoms as well as rapid leukoreduction are critical in the therapeutic management. In the era of next-generation sequencing (NGS), considerable progress has been made in understanding the genetic diversity of AML. However, owing to the small proportion of hyperleukocytic patients generally included in clinical trials, the genomic landscape of hyperleukocytic AML and the prognostic impact of genetic lesions in this specific clinical context have not been described in detail except in a recent study from Taiwan which reported the frequency of mutations in a panel of 20 yeloid genes.

Domaines

Cancer
Fichier principal
Vignette du fichier
Largeaud_2022.pdf (761.49 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04469133 , version 1 (20-02-2024)

Licence

Identifiants

Citer

Laetitia Largeaud, Sarah Bertoli, Emilie Bérard, Suzanne Tavitian, Muriel Picard, et al.. Genomic landscape of hyperleukocytic acute myeloid leukemia. Blood Cancer Journal, 2022, 12 (1), pp.4. ⟨10.1038/s41408-021-00601-5⟩. ⟨hal-04469133⟩
5 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More